The research in our group centers around the use of MRI for radiotherapy with an emphasis on quantitative MRI for prostate cancer. In the phase 3 randomized FLAME trial, we investigate the potential benefit of focal boosting of the tumor in the prostate, as visible on multi-parametric MRI.
Techniques, such as diffusion-weighted MRI, dynamic contrast MRI and T1 and T2 mapping are applied to characterize tumors and response after treatment. In collaboration with the MR-linac consortium, we investigate the potential of the Unity MR-linac for this purpose as it allows daily acquisition of quantitative MRI sequences during radiotherapy.
